Katrina Geannopoulos1,2, Cynthia McMahan1, Ramiro S Maldonado3,4, Akshar Abbott3,5, Jared Knickelbein3,6, Elvira Agron3, Tianxia Wu1, Joseph Snow7, Govind Nair1, Elizabeth Horne1,8, Chuen-Yen Lau9, Avindra Nath1, Emily Y Chew3, Bryan R Smith1. 1. National Institute of National Disorders and Stroke, National Institutes of Health, Bethesda, MD. 2. College of Medicine, University of Illinois, Chicago, IL. 3. National Eye Institute, National Institutes of Health, Bethesda, MD. 4. College of Medicine, University of Kentucky, Lexington, KY. 5. Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN. 6. University of Pittsburgh School of Medicine, Pittsburgh, PA. 7. National Institute of Mental Health, National Institutes of Health, Bethesda, MD. 8. Duke University School of Medicine, Durham, NC; and. 9. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Abstract
BACKGROUND: Retinal measurements correlate with disease progression in patients with multiple sclerosis; however, whether they associate with neurologic disease in people with controlled HIV is unknown. Using spectral domain optical coherence tomography, we evaluated retinal differences between people with HIV and HIV-negative controls and investigated clinical correlates of retinal thinning. METHODS: People with HIV on antiretroviral therapy for at least 1 year and HIV-negative controls recruited from the same communities underwent spectral domain optical coherence tomography, ophthalmic examination, brain MRI, and neuropsychological testing. Retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GC-IPL) thicknesses were compared between groups using analysis of covariance with relevant clinical variables as covariates. Linear regression was used to explore associations of HIV history variables, cognitive domain scores, and MRI volume measurements within the HIV group. RESULTS: The HIV group (n = 69), with long-duration HIV infection (median time from diagnosis 19 years) and outstanding viral control have thinner retinal layers than HIV-negative controls (n = 28), after adjusting for covariates (GC-IPL: P = 0.002; RNFL: P = 0.024). The effect of HIV on GC-IPL thickness was stronger in women than in men (Women: P = 0.011; Men: P = 0.126). GC-IPL thickness is associated with information processing speed in the HIV group (P = 0.007, semipartial r = 0.309). No associations were found with retinal thinning and MRI volumes or HIV factors. CONCLUSIONS: People with HIV on antiretroviral therapy have thinning of the RNFL and GC-IPL of the retina, and women particularly are affected to a greater degree. This retinal thinning was associated with worse performance on tests of information processing speed.
BACKGROUND: Retinal measurements correlate with disease progression in patients with multiple sclerosis; however, whether they associate with neurologic disease in people with controlled HIV is unknown. Using spectral domain optical coherence tomography, we evaluated retinal differences between people with HIV and HIV-negative controls and investigated clinical correlates of retinal thinning. METHODS: People with HIV on antiretroviral therapy for at least 1 year and HIV-negative controls recruited from the same communities underwent spectral domain optical coherence tomography, ophthalmic examination, brain MRI, and neuropsychological testing. Retinal nerve fiber layer (RNFL) and ganglion cell inner plexiform layer (GC-IPL) thicknesses were compared between groups using analysis of covariance with relevant clinical variables as covariates. Linear regression was used to explore associations of HIV history variables, cognitive domain scores, and MRI volume measurements within the HIV group. RESULTS: The HIV group (n = 69), with long-duration HIV infection (median time from diagnosis 19 years) and outstanding viral control have thinner retinal layers than HIV-negative controls (n = 28), after adjusting for covariates (GC-IPL: P = 0.002; RNFL: P = 0.024). The effect of HIV on GC-IPL thickness was stronger in women than in men (Women: P = 0.011; Men: P = 0.126). GC-IPL thickness is associated with information processing speed in the HIV group (P = 0.007, semipartial r = 0.309). No associations were found with retinal thinning and MRI volumes or HIV factors. CONCLUSIONS: People with HIV on antiretroviral therapy have thinning of the RNFL and GC-IPL of the retina, and women particularly are affected to a greater degree. This retinal thinning was associated with worse performance on tests of information processing speed.
Authors: D Huang; E A Swanson; C P Lin; J S Schuman; W G Stinson; W Chang; M R Hee; T Flotte; K Gregory; C A Puliafito Journal: Science Date: 1991-11-22 Impact factor: 47.728
Authors: Nazli Demirkaya; Ferdinand W N M Wit; Thomas J T P van Den Berg; Katherine W Kooij; Maria Prins; Reinier O Schlingemann; Michael D Abramoff; Peter Reiss; Frank D Verbraak Journal: Invest Ophthalmol Vis Sci Date: 2016-03 Impact factor: 4.799
Authors: Ned Sacktor; Richard L Skolasky; Eric Seaberg; Cynthia Munro; James T Becker; Eileen Martin; Ann Ragin; Andrew Levine; Eric Miller Journal: Neurology Date: 2015-12-30 Impact factor: 9.910
Authors: Shiv Saidha; Omar Al-Louzi; John N Ratchford; Pavan Bhargava; Jiwon Oh; Scott D Newsome; Jerry L Prince; Dzung Pham; Snehashis Roy; Peter van Zijl; Laura J Balcer; Elliot M Frohman; Daniel S Reich; Ciprian Crainiceanu; Peter A Calabresi Journal: Ann Neurol Date: 2015-10-01 Impact factor: 10.422
Authors: Charlotte Blokhuis; Nazli Demirkaya; Sophie Cohen; Ferdinand W N M Wit; Henriëtte J Scherpbier; Peter Reiss; Michael D Abramoff; Matthan W A Caan; Charles B L M Majoie; Frank D Verbraak; Dasja Pajkrt Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799
Authors: Elena Garcia-Martin; Diego Rodriguez-Mena; Maria Satue; Carmen Almarcegui; Isabel Dolz; Raquel Alarcia; Maria Seral; Vicente Polo; Jose M Larrosa; Luis E Pablo Journal: Invest Ophthalmol Vis Sci Date: 2014-02-04 Impact factor: 4.799